HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Takes ViruProtect To Russia And Beyond

Executive Summary

Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

You may also be interested in...



Stada Strikes Deal To Launch ViruProtect In Nordics

Stada to launch innovative common cold spray ViruProtect in four Nordic markets in 2021 after striking a new agreement with Sweden's Enzymatica.

UK's 'Muddled' CBD Regulation Open To Legal Challenge

With FSA set to publish its public register detailing which CBD supplements can lawfully remain on the UK market, what can companies do if their product doesn't make the list? Barrister Jonathan Kirk QC set out the limited options left open to firms during a recent webinar.

EU Business Round-Up: Mayoly Spindler Acquires Biohealth, Flarin Gets Funding, Karo Ready For M&A

The latest European consumer health business news: France's Mayoly Spindler acquires Italian supplements specialist Biohealth; UK-based Flarin gets funding to expand at home and abroad; and Sweden's Karo plots further M&A in 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

RS150580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel